Aurobindo Pharma Past Earnings Performance
Past criteria checks 4/6
Aurobindo Pharma's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 5.1% per year. Aurobindo Pharma's return on equity is 9.8%, and it has net margins of 9.9%.
Key information
-3.6%
Earnings growth rate
-3.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 5.1% |
| Return on equity | 9.8% |
| Net Margin | 9.9% |
| Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aurobindo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 278,947 | 27,705 | 38,823 | 0 |
| 30 Sep 23 | 269,500 | 23,254 | 38,143 | 0 |
| 30 Jun 23 | 254,700 | 19,777 | 37,278 | 0 |
| 31 Mar 23 | 248,554 | 19,275 | 36,560 | 0 |
| 31 Dec 22 | 241,918 | 19,977 | 36,478 | 0 |
| 30 Sep 22 | 237,869 | 21,112 | 35,950 | 0 |
| 30 Jun 22 | 239,894 | 23,987 | 35,854 | 0 |
| 31 Mar 22 | 234,555 | 26,482 | 35,751 | 0 |
| 31 Dec 21 | 236,476 | 28,676 | 35,746 | 0 |
| 30 Sep 21 | 240,103 | 52,109 | 35,865 | 0 |
| 30 Jun 21 | 245,518 | 53,217 | 36,395 | 0 |
| 31 Mar 21 | 247,746 | 53,348 | 36,576 | 0 |
| 31 Dec 20 | 249,316 | 53,831 | 36,591 | 0 |
| 30 Sep 20 | 244,617 | 31,421 | 35,761 | 0 |
| 30 Jun 20 | 235,787 | 29,757 | 34,414 | 0 |
| 31 Mar 20 | 230,985 | 28,451 | 33,333 | 0 |
| 31 Dec 19 | 222,323 | 25,666 | 32,224 | 0 |
| 30 Sep 19 | 216,070 | 25,733 | 30,744 | 0 |
| 30 Jun 19 | 207,579 | 25,449 | 29,226 | 0 |
| 31 Mar 19 | 195,636 | 23,647 | 27,389 | 0 |
| 31 Dec 18 | 183,834 | 23,078 | 25,632 | 0 |
| 30 Sep 18 | 174,246 | 21,906 | 24,541 | 0 |
| 30 Jun 18 | 171,091 | 23,603 | 23,473 | 0 |
| 31 Mar 18 | 164,630 | 24,232 | 22,414 | 0 |
| 31 Dec 17 | 159,381 | 24,271 | 20,903 | 0 |
| 30 Sep 17 | 154,903 | 24,107 | 19,953 | 0 |
| 30 Jun 17 | 148,279 | 22,352 | 19,032 | 0 |
| 31 Mar 17 | 149,334 | 23,017 | 18,451 | 0 |
| 31 Dec 16 | 151,565 | 22,809 | 17,799 | 0 |
| 30 Sep 16 | 147,559 | 22,466 | 17,359 | 0 |
| 30 Jun 16 | 143,446 | 20,945 | 16,823 | 0 |
| 31 Mar 16 | 138,162 | 20,251 | 16,019 | 0 |
| 31 Dec 15 | 133,249 | 18,230 | 28,438 | 894 |
| 30 Sep 15 | 129,956 | 16,724 | 27,775 | 894 |
| 30 Jun 15 | 125,433 | 15,928 | 26,938 | 894 |
| 31 Mar 15 | 121,340 | 15,758 | 13,548 | 0 |
| 31 Dec 14 | 112,825 | 16,738 | 17,756 | 624 |
| 30 Sep 14 | 102,756 | 17,069 | 16,210 | 624 |
| 30 Jun 14 | 93,109 | 15,697 | 14,800 | 624 |
| 31 Mar 14 | 81,002 | 11,729 | 13,273 | 624 |
| 31 Dec 13 | 73,736 | 7,797 | 12,261 | 423 |
| 30 Sep 13 | 67,900 | 4,540 | 11,795 | 423 |
| 30 Jun 13 | 63,736 | 4,414 | 11,506 | 423 |
Quality Earnings: 524804 has high quality earnings.
Growing Profit Margin: 524804's current net profit margins (9.9%) are higher than last year (8.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524804's earnings have declined by 3.6% per year over the past 5 years.
Accelerating Growth: 524804's earnings growth over the past year (38.7%) exceeds its 5-year average (-3.6% per year).
Earnings vs Industry: 524804 earnings growth over the past year (38.7%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 524804's Return on Equity (9.8%) is considered low.